Tonix Pharmaceuticals Holding Corp

-0.03 (-2.61%)
Products, Regulatory, Other Pre-Announcement

Tonix Pharmaceuticals Announces Plan To Complete The Phase 3 Relief Study Of TNX-102 SL

Published: 09/29/2020 20:35 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 Relief Study of Tnx-102 Sl for Management of Fibromyalgia With Currently Enrolled Participants Based on Results of Interim Analysis.
Tonix Pharmaceuticals Holding - Topline Results of Full Study Expected Q4 2020.
Tonix Pharmaceuticals - Relief Study Protocol Formally Amended Mid-study to Conform to FDA Guidance During Covid-19 Public Health Emergency.
Tonix Pharmaceuticals - Currently Enrolling a 2nd Potential Pivotal Phase 3 Study of Tnx-102 Sl in Fibromyalgia, With Topline Data Expected H2 2021.